



## Company Overview

Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.

## Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

Mar 1 2021, 8:30 AM EST

## Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China

Jan 26 2021, 9:00 AM EST

## Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

Jan 5 2021, 9:00 AM EST

## Stock Overview

Symbol	QLGN
Exchange	Nasdaq
Market Cap	77.45m
Last Price	\$2.90
52-Week Range	\$2.85 - \$19.75

03/04/2021 04:00 PM EST

## Investor Relations

LHA Investor Relations
2121 Avenue of the Stars
Suite 2970
Los Angeles, CA 90067
T: 310-691-7100

## Management Team

### Michael S. Poirier

President, CEO and Chairman

### Christopher L. Lotz

Chief Financial Officer

### Amy Broidrick

Executive Vice President, Chief Strategy Officer and Director

### Shishir K. Sinha

Vice President, Operations, Corporate Secretary

### Wajdi Abdul-Ahad, PhD

Vice President, R&D, Chief Scientific Officer

## Qualigen Therapeutics, Inc.

2042 Corte del Nogal  
Suite B  
Carlsbad, CA 92011

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.